Evidence map›Paper›PMID 33814463›Full record

ArticleJournal of Parkinson's disease2021

Lipidomics Prediction of Parkinson's Disease Severity: A Machine-Learning Analysis.

Hila Avisar, Cristina Guardia-Laguarta, Estela Area-Gomez, Matthew Surface, Amanda K Chan, Roy N Alcalay, Boaz Lerner

Open access · greenAbstract read
In one paragraph

Article in Journal of Parkinson's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Hila AvisarDepartment of Industrial Engineering & Management, Ben-Gurion University of the Negev, Israel.
Cristina Guardia-LaguartaDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Estela Area-GomezDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Matthew SurfaceDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Amanda K ChanDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Roy N AlcalayDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Boaz LernerDepartment of Industrial Engineering & Management, Ben-Gurion University of the Negev, Israel.
Columbia University Irving Medical Center · USBen-Gurion University of the Negev · IL

Funding

The role of glucocerebrosidase in Parkinson's diseaseK02NS080915 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALCALAY, ROY · 2012 to 2016
$905k
NINDS NIH HHS K02 NS080915
6 · The paper itself

Abstract

backgroundThe role of the lipidome as a biomarker for Parkinson's disease (PD) is a relatively new field that currently only focuses on PD diagnosis.

objectiveTo identify a relevant lipidome signature for PD severity markers.

methodsDisease severity of 149 PD patients was assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) and the Montreal Cognitive Assessment (MoCA). The lipid composition of whole blood samples was analyzed, consisting of 517 lipid species from 37 classes; these included all major classes of glycerophospholipids, sphingolipids, glycerolipids, and sterols. To handle the high number of lipids, the selection of lipid species and classes was consolidated via analysis of interrelations between lipidomics and disease severity prediction using the random forest machine-learning algorithm aided by conventional statistical methods.

resultsSpecific lipid classes dihydrosphingomyelin (dhSM), plasmalogen phosphatidylethanolamine (PEp), glucosylceramide (GlcCer), dihydro globotriaosylceramide (dhGB3), and to a lesser degree dihydro GM3 ganglioside (dhGM3), as well as species dhSM(20:0), PEp(38:6), PEp(42:7), GlcCer(16:0), GlcCer(24:1), dhGM3(22:0), dhGM3(16:0), and dhGB3(16:0) contribute to PD severity prediction of UPDRS III score. These, together with age, age at onset, and disease duration, also contribute to prediction of UPDRS total score. We demonstrate that certain lipid classes and species interrelate differently with the degree of severity of motor symptoms between men and women, and that predicting intermediate disease stages is more accurate than predicting less or more severe stages.

conclusionUsing machine-learning algorithms and methodologies, we identified lipid signatures that enable prediction of motor severity in PD. Future studies should focus on identifying the biological mechanisms linking GlcCer, dhGB3, dhSM, and PEp with PD severity.

Indexed as

LipidomicsParkinson DiseaseBiomarkersFemaleHumansLipidsMachine LearningMaleSeverity of Illness IndexBiomarkersLipidslipidomelipidomicsmachine learningParkinson’s disease (PD)PD severityUPDRS

Identifiers

PMID33814463
PMCPMC8355022
OpenAlexW3151552372

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.